COMMUNIQUÉS West-GlobeNewswire

-
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
24/02/2025 -
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
24/02/2025 -
OrganOx Completes $142 Million Equity Financing Led by HealthQuest Capital
24/02/2025 -
SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS™ FIRST-IN-HUMAN STUDY
24/02/2025 -
WW International, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
24/02/2025 -
Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances
24/02/2025 -
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
24/02/2025 -
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
23/02/2025 -
Bay Area Therapy Center Offers Specialized Therapy for Overcoming Communication and Relationship Issues in San Francisco
23/02/2025 -
Hospital shooting highlights the dangers and violence nurses often face at work
23/02/2025 -
Bay Area Cognitive Behavioral Therapy Center Expands Treatment Offerings with Acceptance and Commitment Therapy
22/02/2025 -
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
22/02/2025 -
Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn
22/02/2025 -
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
22/02/2025 -
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
21/02/2025 -
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21/02/2025 -
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.
21/02/2025 -
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares of Common Stock
21/02/2025 -
Fortrea to Add Erin L. Russell to Board of Directors
21/02/2025
Pages